Lemuteporfin

DB04980InvestigationalSmall molecule

Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

Chemical structure of Lemuteporfin
Mechanism
Curator reviewed
Primary indication
Intended for the treatment of benign prostatic hyperplasia and prostrate disorders.Curator reviewed
Formula / weight
C44H48N4O10 · 792.886 g/mol (avg)
Code names
EA 6 · QLT-0074

Resolves to

Structure
InChIKeyPUTVMYIZBFOAFU-MTVFQPQZSA-NSMILESCOC(=O)C1C(=CC=C2\C3=C\C4=N\C(=C/C5=C(C)C(CCC(=O)OCCO)=C(N5)\C=C5/N=C(/C=C(\N3)C12C)C(C)=C5CCC(=O)OCCO)\C(C=C)=C4C)C(=O)OC

What you can answer from here — as of March 26, 2021

3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of Lemuteporfin, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account